"The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC" takes up the trial that the panel calls the biggest ...
Two new studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide new insight into how the ...
Olive pollen immunotherapy was linked to improved allergy symptoms and fewer asthma exacerbations, with no severe systemic ...
Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, announced that three ...
Immorta Bio, Inc., a biotechnology company pioneering therapies targeting fundamental mechanisms of aging, today announced ...
A 2023 review from Fudan University documents how Chinese clinical trials and single-cell omics studies are transforming the ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
Researchers used a CRISPR screen to identify a key molecular pathway that drives exhaustion in cancer-fighting immune cells, ...
In "Closing the Gap: Underused Consolidation Immunotherapy in Limited-Stage SCLC," our experts confront a stubborn disconnect ...
Health and Me on MSN
FDA approves new treatment option for bladder cancer unresponsive to standard immunotherapy
The US Food and Drug Administration recently approved an alternative treatment option for patients with BCG-unresponsive high ...
The study showed OncoPrism-NSCLC significantly predicted overall response and identified the subset of patients with doubled median overall survival i ...
The FDA expanded approval of Anktiva for bladder cancer. The agent is the first approved treatment for BCG-unresponsive, high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results